Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions
Open Access
- 11 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (9) , 2324-2338
Abstract
Huntington's disease (HD) is an autosomal dominant, neurodegenerative disorder that can be characterized by the presence of protein inclusions containing mutant huntingtin within a subset of neurons in the brain. Since their discovery, the relevance of inclusions to disease pathology has been controversial. We show using super-resolution fluorescence imaging and Förster resonance energy transfer (FRET) in live cells, that mutant huntingtin fragments can form two morphologically and conformationally distinct inclusion types. Using fluorescence recovery after photobleaching (FRAP), we demonstrate that the two huntingtin inclusion types have unique dynamic properties. The ability to form one or the other type of inclusion can be influenced by the phosphorylation state of serine residues at amino acid positions 13 and 16 within the huntingtin protein. We can define two types of inclusions: fibrillar, which are tightly packed, do not exchange protein with the soluble phase, and result from phospho-modification at serines 13 and 16 of the N17 domain, and globular, which are loosely packed, can readily exchange with the soluble phase, and are not phosphorylated in N17. We hypothesize that the protective effect of N17 phosphorylation or phospho-mimicry seen in animal models, at the level of protein inclusions with elevated huntingtin levels, is to induce a conformation of the huntingtin amino-terminus that causes fragments to form tightly packed inclusions that do not exit the insoluble phase, and hence exert less toxicity. The identification of these sub-types of huntingtin inclusions could allow for drug discovery to promote protective inclusions of mutant huntingtin protein in HD.Keywords
This publication has 64 references indexed in Scilit:
- Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93%Nature Communications, 2012
- Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD MiceNeuron, 2009
- Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils—current statusJournal of Chemical Biology, 2009
- Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamicsNeurobiology of Disease, 2008
- A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouseProceedings of the National Academy of Sciences, 2007
- Huntingtin facilitates dynein/dynactin-mediated vesicle transportProceedings of the National Academy of Sciences, 2007
- Flanking sequences profoundly alter polyglutamine toxicity in yeastProceedings of the National Academy of Sciences, 2006
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004
- An improved cyan fluorescent protein variant useful for FRETNature Biotechnology, 2004